Advertisement

Intensive Care Medicine

, Volume 16, Supplement 3, pp S206–S211 | Cite as

The emergence of antibiotic resistance: Myths and facts in clinical practice

  • J. M. T. Hamilton-Miller
Article

Abstract

Selection pressure, caused by the use of antibiotics — especially in hospitals — is the main factor responsible for the emergence of antibiotic-resistant bacteria. Resistance can arise endogenously by mutation (onestep, as found forMycobacterium tuberculosis to rifampicin, or multi-step, as in gonococci to benzylpenicillin), or exogenously by transfer of R-factors. Mechanisms of resistance may involve a decrease in permeability, chemical modification of the antibiotic, or a change in the affinity of the target site. There are many misconceptions concerning the incidence, nature and spread of antibiotic resistance, and some of the most important of these are discussed. The emergence and spread of resistance can be controlled by adhering to antibiotic policies and by preventing or controlling outbreaks of infection. The importance of resistant organisms can be diminished by the development of new antibiotic agents, preferably containing new chemical entities.

Key words

Antibiotic resistance Infection 

References

  1. 1.
    Davies J (1989) The new quinolones. Back to the future. Rev Infect Dis [Suppl 5] 11:S898-S901Google Scholar
  2. 2.
    Williams REO (1973) Benefit and mischief from commensal bacteria. J Clin Pathol 26:811–818Google Scholar
  3. 3.
    Kirrstetter R, Durckheimer W (1989) Development of new β-lactam antibiotics, derived from natural and synthetic sources. Die Pharmazie 44:177–185Google Scholar
  4. 4.
    Hamilton-Miller JMT (1984) Use and abuse of antibiotics. Br J Clin Pharmacol 18:469–474Google Scholar
  5. 5.
    McDermott W (1982) Social ramifications of control of microbial disease. Johns Hopkins Med J 151:302–312Google Scholar
  6. 6.
    Brumfitt W, Hamilton-Miller JMT (1989) Methicillin-resistant Staphylococcus aureus. New Engl J Med 320:1188–1196Google Scholar
  7. 7.
    Barber M, Csillag A (1958) Staphylococcal infection resistant to chloramphenicol, erythromycin and novobiocin. Br Med J ii:1377–1380Google Scholar
  8. 8.
    Price DJE, Sleigh JD (1970) Control of infection due to Klebsiella aerogenes in a neurosurgical unit by withdrawal of all antibiotics. Lancet i:230–233Google Scholar
  9. 9.
    Perlman D (1980) Some problems on the new horizons of applied microbiology. Dev Indust Microbiol 21:XV-XXIIIGoogle Scholar
  10. 10.
    Hamilton-Miller JMT, Iliffe A (1985) Antimicrobial resistance in coagulase-negative staphylococci. J Med Microbiol 19:217–226Google Scholar
  11. 11.
    Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB (1989) Cross-resistance to fluoroquinolones in multiple-antibiotic resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 33:1318–1325Google Scholar
  12. 12.
    Trallero FP, Arenzana JMG, Egana MU (1989) Erythromycin resistance in streptococci. Lancet ii:444–445Google Scholar
  13. 13.
    Klugman KP, Koornhof JH (1989) Worldwide increase in pneumococcal antibiotic resistance. Lancet ii:444Google Scholar
  14. 14.
    Kunin CM (1985) The responsibility of the Infectious Disease Community for the optimal use of antimicrobial agents. J Infect Dis 151:388–398Google Scholar
  15. 15.
    Waksman SA (1949) Streptomycin: nature and practical applications. Bailliere, LondonGoogle Scholar
  16. 16.
    Binda G, Domenichini E, Gottardi A, Orlandi B, Ortelli E, Pacini B, Fowst G (1971) Rifampicin, a general review. Arzneimitt Forsch 21:1907–1978Google Scholar
  17. 17.
    Stamey TA, Bragonje J (1976) Resistance to nalidixic acid. A misconception due to underdosage. J Am Med Ass 236:1857–1860Google Scholar
  18. 18.
    Phillips I, Shannon K (1989) Class I β-lactamases: induction and derepression. Drugs 37:402–407Google Scholar
  19. 19.
    Hamilton-Miller JMT (1974) Non-emergence of polyene-resistant yeasts: An hypothesis. Microbios 10A:91–95Google Scholar
  20. 20.
    O'Brien TF et al. (1987) Resistance of bacteria to antibacterial agents: Report of Task Force 2. Rev Infect Dis [Suppl 3] 9:S244-S260Google Scholar
  21. 21.
    Col NF, O'Connor RW (1987) Estimating worldwide current antibiotic usage: Report of Task Force 1. Rev Infect Dis [Suppl 3] 9:S 232–243Google Scholar
  22. 22.
    Hamilton-Miller JMT, Purves D (1986) Trimethoprim resistance and trimethoprim usage in and around the Royal Free Hospital in 1985. J Antimicrob Chemother 18:643–644Google Scholar
  23. 23.
    Gruneberg RN (1986) The use of antibiotics in urinary tract infections. In: Asscher AW, Brumfitt W (eds) Microbial diseases in nephrology. Wiley, Chichester, pp 311–323Google Scholar
  24. 24.
    Hamilton-Miller JMT (1972) A comparative study of amphotericin B, clotrimazole and 5-fluorocytosine against clinically isolated yeasts. Sabouraudia 10:276–283Google Scholar
  25. 25.
    Loulergue J, Pinon G, Laudat P, Audurier A (1984) La resistance a la fosfomycine chez Staphylococcus saprophyticus et chez les autres especes de staphylocoques coagulase negative. Ann Microbiol (Institut Pasteur) 135A:239–247Google Scholar
  26. 26.
    Smith DH (1967) R-factor infection of Escherichia coli lyophilized in 1946. J Bacteriol 94:2071–2072Google Scholar
  27. 27.
    Hamilton-Miller JMT, Grey D (1975) Resistance to trimethoprim in Klebsiellae isolated before its introduction. J Antimicrob Chemother 1:213–218Google Scholar
  28. 28.
    Milatovic D, Braveny I (1987) Development of resistance during antibiotic therapy. Eur J Clin Microb 6:1–11Google Scholar
  29. 29.
    Brumfitt W, Hamilton-Miller JMT (1987) Principles and practice of antimicrobial chemotherapy. In: Speight TM (ed) Avery's drug treatment, 3rd edn. ADIS Press, Auckland, pp 1207–1235Google Scholar
  30. 30.
    Hamilton-Miller JMT (1978) Use of laboratory tests in predicting the therapeutic efficacy of antimicrobial compounds. In: Brumfitt W, Hamilton-Miller JMT (eds) New perspectives in clinical microbiology. Kluwer, London, pp 31–43Google Scholar
  31. 31.
    Sanders CC, Sanders WE, Goering RV, Werner V (1984) Selection of miltiple antibiotic resistance by quinolones, β-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 26:797–801Google Scholar
  32. 32.
    Smith HW (1976) Mutants of Klebsiella pneumoniae resistant to several antibiotics. Nature 259:307–308Google Scholar
  33. 33.
    Gutmann L, Williamson R, Moreau N, Kitzis M-D, Collatz E, Acar JF, Goldstein FW (1985) Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol with alterations in outer membrane proteins of Klebsiella, Enterobacter and Serratia. J Infect Dis 151:501–507Google Scholar
  34. 34.
    Lorian V, Gardner DA (1985) Bacterial resistance to antibiotics in American hospitals. Chemioterapia 4:14–18Google Scholar
  35. 35.
    Young LS, Hindler J (1986) Aminoglycoside resistance: A worldwide perspective. Am J Med [Suppl 6B] 80:15–22Google Scholar
  36. 36.
    Lane MM, Parker DE, Flournoy DJ (1985) Trends in bacterial susceptibility to antimicrobial agents. Chemotherapy 31:433–439Google Scholar
  37. 37.
    Flournoy DJ (1985) Influence of aminoglycoside usage of susceptibilities. Chemotherapy 31:178–180Google Scholar
  38. 38.
    Kresken M, Wiedemann B (1986) Development of resistance in the past decade in Central Europe. J Antimicrob Chemother [Suppl C] 18:235–242Google Scholar
  39. 39.
    O'Brien T et al. (1986) Resistance to antibiotics at medical centres in different parts of the world. J Antimicrob Chemother [Suppl C] 18:243–253Google Scholar
  40. 40.
    Maple P, Hamilton-Miller JMT, Brumfitt W (1989) Ciprofloxacin resistance in methicillin and gentamicin-resistant Staphylococcus aureus. Eur Clin Microbiol Infect Dis 8:622–624Google Scholar
  41. 41.
    Bosso JA, Allen JE, Matsen JM (1989) Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of new antibiotics. Antimicrob Agents Chemother 33:526–528Google Scholar
  42. 42.
    Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K (1989) Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 33:1451–1456Google Scholar
  43. 43.
    Greek Society for Microbiology (1989) Antibiotic resistance among Gram-negative bacilli in 19 Greek hospitals. J Hosp Infect 14:177–181Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • J. M. T. Hamilton-Miller
    • 1
  1. 1.Department of Medical MicrobiologyRoyal Free Hospital and School of MedicineLondonUK

Personalised recommendations